Sugi Predict

Sugi Predict / Targets / PIK3C2B

PIK3C2B

Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta · O00750 · PIK3C2B on Sugi Atlas →

27,034 patent compounds predicted against PIK3C2B, 20,862 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL11465 SCHEMBL11465 0.54 6/20
SCHEMBL11515 SCHEMBL11515 0.58 5/20
SCHEMBL10593 SCHEMBL10593 0.54 5/20
SCHEMBL129487 SCHEMBL129487 0.53 3/20
Dactolisib Dactolisib (SCHEMBL143623) 1.00 2/20
Buparlisib Buparlisib (SCHEMBL146956) 1.00 2/20
Buparlisib Buparlisib (SCHEMBL143412) 0.98 2/20
SCHEMBL48734 SCHEMBL48734 0.61 2/20
SCHEMBL48579 SCHEMBL48579 0.58 2/20
SCHEMBL188602 SCHEMBL188602 0.56 2/20
SCHEMBL48745 SCHEMBL48745 0.52 2/20
SCHEMBL49300 SCHEMBL49300 0.51 2/20
SCHEMBL49545 SCHEMBL49545 0.51 2/20
SCHEMBL48534 SCHEMBL48534 0.50 2/20
SCHEMBL48887 SCHEMBL48887 0.50 2/20
SCHEMBL48754 SCHEMBL48754 0.49 2/20
SCHEMBL48913 SCHEMBL48913 0.49 2/20
SCHEMBL48640 SCHEMBL48640 0.48 2/20
SCHEMBL48688 SCHEMBL48688 0.48 2/20
SCHEMBL48716 SCHEMBL48716 0.48 2/20

Clinical trials — most relevant to PIK3C2B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Adjuvant Low Dose Aspirin in Colorectal Cancer PHASE3ACTIVE_NOT_RECRUITING
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma. PHASE2UNKNOWN
Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome PHASE2WITHDRAWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) PHASE2COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules PHASE1COMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome nanRECRUITING
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary Immunodeficiencies nanNOT_YET_RECRUITING
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer nanWITHDRAWN
Exploring the Link Between Cancer Genetics and PPSP nanUNKNOWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Study of Proteus Syndrome and Related Congenital Disorders nanRECRUITING
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PIK3C2B binder may also engage these)

ProteinNameSimilarity
Q9Z136 — 0.998 Q9Z136 →
Q9EP53 — 0.997 Q9EP53 →
Q9Y3R5 — 0.996 Q9Y3R5 →
O70173 — 0.996 O70173 →
Q3UHQ6 — 0.996 Q3UHQ6 →
Q9D684 — 0.995 Q9D684 →
O88480 — 0.995 O88480 →
Q155Q3 — 0.994 Q155Q3 →
Q5PQS3 — 0.994 Q5PQS3 →
A5D794 — 0.994 A5D794 →
PTPN13 Tyrosine-protein phosphatase non-receptor type 13 0.994 landscape →
A1A4J7 — 0.994 A1A4J7 →
Q8VDP4 — 0.994 Q8VDP4 →
Q7Z3E5 — 0.994 Q7Z3E5 →
A0A0G2JUG7 — 0.994 A0A0G2JUG7 →
Q14D04 — 0.994 Q14D04 →
Q80Y83 — 0.994 Q80Y83 →
Q8VDR9 — 0.994 Q8VDR9 →
O75815 — 0.994 O75815 →
Q91VB4 — 0.993 Q91VB4 →
Q92574 — 0.993 Q92574 →
Q4G0A6 — 0.993 Q4G0A6 →
Q2HJE1 — 0.993 Q2HJE1 →
A2BID5 — 0.993 A2BID5 →
Q6P1Y8 — 0.993 Q6P1Y8 →
Q3UQI9 — 0.993 Q3UQI9 →
A0M8T5 — 0.993 A0M8T5 →
O70167 — 0.993 O70167 →
Q09YG9 — 0.993 Q09YG9 →
Q09YJ3 — 0.993 Q09YJ3 →